Trial Profile
A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Human papillomavirus 6/11 vaccine recombinant bivalent Xiamen (Primary) ; Aluminium
- Indications Condylomata acuminata
- Focus Adverse reactions
- 10 Feb 2022 Planned End Date changed from 31 Jul 2021 to 31 May 2022.
- 13 Sep 2020 Planned End Date changed from 31 Jul 2020 to 31 Jul 2021.
- 29 Apr 2020 Planned End Date changed from 31 Mar 2020 to 31 Jul 2020.